Phase 1 Study to Find the Right Starting Dose of Sacituzumab Govitecan for Adults with Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Led by Gilead Sciences · Updated on 2026-06-02
30
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying sacituzumab govitecan-hziy to understand its safety and dosing in adults with advanced or metastatic solid tumors who also have moderate liver problems. This phase 1 study focuses on participants with varying liver function to find appropriate dosing while monitoring side effects and drug behavior in the body.
Participants with moderate liver impairment will receive increasing doses of sacituzumab govitecan-hziy on Days 1 and 8, starting from 5 mgkg and potentially increasing to 10 mgkg if safe. Those with normal liver function will receive a fixed dose of 10 mgkg on the same schedule. After completing the study treatment, participants benefiting from the drug may continue treatment in a related extension study sponsored by Gilead Sciences.
Throughout the study, participants will be closely monitored for side effects, serious adverse events, and dose-limiting toxicities up to Day 38. Blood samples will be collected to study drug levels and immune responses on specific days. The study aims to gather detailed safety and pharmacokinetic data to guide future dosing recommendations, with participation lasting through the initial treatment and potential rollover study.
CONDITIONS
Brief Title
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Research Team
G
Gilead Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Advanced/metastatic solid tumor with moderate liver impairment
Advanced/metastatic solid tumor with normal liver function
What it is
Intravenous administration of sacituzumab govitecan-hziy to adults with advanced or metastatic solid tumors and moderate hepatic impairment.
Intravenous administration of sacituzumab govitecan-hziy to adults with advanced or metastatic solid tumors and normal liver function.
Role in trial
Evaluates safety, dose-limiting toxicities, and pharmacokinetics in participants with moderate hepatic impairment.
Serves as a comparison for safety and pharmacokinetics in participants with normal hepatic function.
Primary use
Study intervention to understand safety and pharmacokinetics of sacituzumab govitecan-hziy in patients with moderate liver impairment.
Study intervention to establish safety and pharmacokinetics reference for sacituzumab govitecan-hziy in patients with normal liver function.
How it is given or performed
Sacituzumab govitecan-hziy is administered by intravenous infusion.
Sacituzumab govitecan-hziy is administered by intravenous infusion.
Evidence status
Safety, pharmacokinetics, and dose-limiting toxicity results in moderate liver impairment are not yet established; ongoing clinical investigation.
Safety, pharmacokinetics, and dose-limiting toxicity results in normal liver function are not yet established; ongoing clinical investigation.
Important limitations
Small population size and single-arm design limit interpretation of safety and dose-limiting toxicities for moderate hepatic impairment, and results will require confirmation in larger studies.
Small cohort and non-randomized comparison limit the generalizability of findings for patients with normal liver function.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults with histologically confirmed advanced or metastatic solid tumor, measurable or nonmeasurable
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Adequate blood counts without transfusions or growth factors within 2 weeks before starting study drug (hemoglobin 9 g/dL, absolute neutrophil count 1,500/mm^3, platelets 100,000/bcL)
Creatinine clearance 30 mL/min by Cockcroft-Gault equation
Normal liver function (total bilirubin upper limit of normal and AST 3�d7 upper limit) for normal hepatic function group
Moderate hepatic impairment (total bilirubin between 1.5 and 3.0 times upper limit of normal) for moderate hepatic function group
For hepatic encephalopathy patients, ability to provide informed consent as judged by investigator
You will not qualify if you...
Poor venous access
Donated or lost 500 mL or more of blood recently or plans to donate during study
Prior anticancer biologic therapy within 4 weeks before Day 1
Prior chemotherapy, targeted therapy, or radiation within 2 weeks before Day 1 without recovery from side effects to Grade 1 or less
Prior irinotecan treatment within 4 weeks before Day 1
Active second malignancy
Known active central nervous system metastases or carcinomatous meningitis
History of cardiac disease
Active serious infection
Active chronic inflammatory bowel disease or GI perforation within 6 months
High-dose systemic corticosteroid use within 2 weeks before study
Use of strong inhibitors or inducers of UGT1A1 enzyme
Known Gilbert's disease
For normal hepatic function group, pre-existing liver or kidney problems affecting drug metabolism
For moderate hepatic impairment group, recent significant liver disease symptoms, tense ascites, acute viral hepatitis within 1 month, hepatorenal syndrome, TIPS placement, or active severe encephalopathy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 38 days
Participants receive sacituzumab govitecan-hziy intravenously on Days 1 and 8. Dose levels vary by group, with dose escalation for participants with moderate hepatic impairment and a fixed dose for those with normal liver function.
2 visits (in-person) on Days 1 and 8
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluation of PLN-101095 Combined With Pembrolizumab for Adults With Advanced or Metastatic Solid Tumors After Progression on Immunotherapy
Predicting Post-Hepatectomy Liver Failure Using Resected Normal Liver Tissue Volume in Liver Cancer Surgery
Phase 1 Study of AB122-Based Treatments for Adults With Advanced or Metastatic Solid Tumors
Study of Safety and Function of CRISPR-Edited Donor Liver Transplants Removing HLA-A, HLA-B, and Class II Genes in Adults with End-Stage Liver Disease
Integrating CT Volumetry with Vascular Deformation Mapping to Predict Liver Failure After Major Hepatectomy
Study of Artificial Liver Support System Treatment for Liver Failure Caused by Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
Study on Safety and Effectiveness of Citrate Anticoagulation in Continuous Kidney Therapy for Adults with Liver Failure and Severe Shock
Effects of Empagliflozin Compared to Placebo on Sodium Excretion and Fluid Balance in Patients With Cirrhosis and Ascites Using a Crossover Design
Study of Fecal Microbiota Transplantation Safety and Effects in Adults With Acute-on-chronic Liver Failure
Registry Study to Improve Treatment and Care for Liver Failure Patients in China
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Thomas M Cardillo, Serengulam V Govindan, Robert M Sharkey...
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.
Thomas M Cardillo, Robert M Sharkey, Diane L Rossi...
Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.
Thomas M Cardillo, Serengulam V Govindan, Robert M Sharkey...